The novel mechanism of lenalidomide activity
Lenalidomide acts by a novel drug mechanism—modulation of the substrate specificity of the CRL4[CRBN] E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4[CRBN] . Subsequent proteasomal ...
Blood . 2015 Oct 5;126(21):2366–2369. doi: 10.1182/blood-2015-07-567958 The novel mechanism of lenalidomide activity Emma C Fink Emma C Fink 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA Find articles by Emma C Fink 1 , Benjamin L Ebert Benjamin L Ebert 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA Find articles by Benjamin L Ebert 1, ✉ Author information Article notes Copyright and License information 1 Brigham and Women’s Hospital, Division of Hematology, Boston, MA ✉ Corresponding author. Received 2015 Jul 1; Accepted 2015 Sep 23; Issue date 2015 No
saved by
related reading
- Lysosome-targeting chimeras evolve | Nature Chemical Biologynature.com
- Targeting telomerase for cancer therapy | Oncogenenature.com
- Protein degradation reaches further outnature.com
- Lysosome-targeting chimaeras for degradation of extracellular proteins | Naturenature.com
- PDB101: Molecule of the Month: PROTACs and Molecular Glue Degraderspdb101.rcsb.org
- Summing up cancer stem cellsnature.com
- The blood cancer that became solvableworksinprogress.news
- Longevity FAQ - Laura Demingldeming.com
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemianature.com
- Mechanisms of Immunosuppression - Holland-Frei Cancer Medicine - NCBI Bookshelfncbi.nlm.nih.gov
- The dTAG system for immediate and target-specific protein degradationpmc.ncbi.nlm.nih.gov
- The current state of the art and future trends in RAS-targeted cancer therapiesnature.com